These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26028676)

  • 1. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
    Lee YR; Kang MH; Park HM
    Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
    Elliott JW; Cripps P; Marrington AM; Grant IA; Blackwood L
    Vet Comp Oncol; 2013 Sep; 11(3):185-98. PubMed ID: 22372620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiomyopathy in a dog with multicentric lymphoma following treatment with several anthracyclines.
    Tagawa M; Shimbo G; Uemura A; Matsumoto K
    Open Vet J; 2021; 11(1):6-10. PubMed ID: 33898277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
    Hatake K; Miura Y
    Lancet; 1996 May; 347(9013):1485. PubMed ID: 8676653
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anthracycline-induced cardiotoxicity: report of fatal cases].
    Vargas-Neri JL; Castelán-Martínez OD; de Jesús Estrada-Loza M; Betanzos-Cabrera Y; Rivas-Ruiz R
    Rev Med Inst Mex Seguro Soc; 2016; 54(3):404-8. PubMed ID: 27100990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity associated with epirubicin treatments in a large case series of dogs.
    Marrington AM; Killick DR; Grant IA; Blackwood L
    Vet Comp Oncol; 2012 Jun; 10(2):113-23. PubMed ID: 22236353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
    Jensen BV; Skovsgaard T; Nielsen SL
    Ann Oncol; 2002 May; 13(5):699-709. PubMed ID: 12075737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
    Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
    J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective clinical evaluation of serum cardiac troponin T in dogs admitted to a veterinary teaching hospital.
    DeFrancesco TC; Atkins CE; Keene BW; Coats JR; Hauck ML
    J Vet Intern Med; 2002; 16(5):553-7. PubMed ID: 12322705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of serial cardiac evaluations during doxorubicin-based chemotherapy in small- to medium-sized dogs with multicentric lymphoma.
    Tang YS; Wang SL
    Vet J; 2024 Jun; 305():106134. PubMed ID: 38750812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
    Jensen BV; Nielsen SL; Skovsgaard T
    Lancet; 1996 Feb; 347(8997):297-9. PubMed ID: 8569365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
    Katamadze NA; Lartsuliani KP; Kiknadze MP
    Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
    Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
    J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy].
    Jensen BV; Nielsen SL; Jensen TS
    Ugeskr Laeger; 1997 Mar; 159(13):1945-9. PubMed ID: 9123633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of cardiac troponin I (cTnI) and tissue velocity imaging (TVI) in 14 dogs with malignant lymphoma undergoing chemotherapy treatment with doxorubicin.
    Tater G; Eberle N; Hungerbuehler S; Joetzke A; Nolte I; Wess G; Betz D
    Vet Comp Oncol; 2017 Mar; 15(1):55-64. PubMed ID: 25664927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible Cardiomyopathy After Epirubicin Administration.
    Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M
    Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.